Drug intelligence / Profile preview

Giniwa U

Development stage: Unknown
Lead developer: Zinereo Pharma
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral

Overview

Giniwa U is a probiotic food supplement developed by Zinereo Pharma, a Spanish biotechnology company specializing in microbiome-based solutions. As part of the Giniwa product family, which includes formulations for vaginal (Giniwa V) and general microbiome (Giniwa M) health, Giniwa U is specifically designed to support the uterine microbiome. The product aims to promote the colonization of beneficial bacteria within the uterus to maintain a healthy microbial balance, which is increasingly recognized as a critical factor in reproductive health and fertility. By preventing uterine dysbiosis, Giniwa U is intended to support overall uterine wellness and potentially improve outcomes related to reproductive medicine.

Brand names: Giniwa U

Beyond the preview

Go deeper on Giniwa U.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Giniwa U.

Explore the full profile